Phase 1 Data on the Vaccitech Prostate Cancer Vaccine Presented at ASCO 2018

Jun 4, 2018

Vaccitech Limited, a UK company developing products to treat and prevent multiple infectious diseases and cancer, today announced the presentation of Phase 1 prostate cancer vaccine data at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

In this “window” study, funded by the European Commission FP7 programme, 40 patients with low or intermediate prostate cancer scheduled for surgery or under active surveillance received a single chimpanzee Oxford adenovirus encoding the 5T4 tumour antigen (ChAdOx.5T4) vaccination followed either 1 or 4 weeks later by a modified vaccinia Ankara encoding the same antigen (MVA.5T4). Over 60% of patients had responses in ex vivo ELISpots following vaccination, which included both CD4+ and CD8+ T cells. In addition, 5T4-reactive tissue infiltrating lymphocytes were isolated from post-surgical specimens and biopsies, potentially indicating trafficking of newly-induced T cells to the tumour site.

Given these promising data, a Phase 2 UK study combining the ChAdOx-MVA 5T4 therapeutic vaccine with a checkpoint inhibitor will begin in intermediate risk and metastatic prostate cancer within the next two months.

Vaccitech is developing six products that are based on inducing cellular immune responses using non-replicating viral vectors for treatment or prophylaxis against diseases at various stages. The company, spun out by Oxford University Innovation in 2016, is commercialising the research of vaccine development specialists Adrian Hill and Sarah Gilbert, who developed the underpinning technology at Oxford University’s Jenner Institute.


Notes to Editor

About Vaccitech

Vaccitech’s 5T4 viral vector vaccine is designed to induce CD4+ and CD8+ T cells against the oncofoetal antigen 5T4, which is highly expressed in several cancers including prostate, renal, lung, breast and colorectal. Vaccitech uses clinically validated non-replicating viral vectors for the use of prophylaxis or treatment for conditions in which the induction of T cells, along with antibodies, are critical for prevention or control. Prostate cancer is the 4th most common & 5th leading cause of cancer death in men. Vaccitech ( is a clinical stage vaccine company originating from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centres in the world. The founders of the company are Professor Adrian Hill (Director of the Jenner Institute) and Professor Sarah Gilbert (Lead in influenza and MERS), who combine their exceptional scientific skills with regulatory and manufacturing experience. The management team has decades of experience in the development of vaccine products.